Diabetes

ADA 2020: Glycemic control was worse for black patients who experienced hurried interaction with healthcare providers than for those who did not, a new study reports.

ADA 2020. Improvement in glycemic control among US veterans was seen across 5 study sites and was sustained at 18 months after study initiation, says study reported at the ADA 80th Virtual Scientific Sessions.

ADA 2020. An investigational once-weekly insulin proved comparable in safety and efficacy to traditional once-daily insulin glargine in findings presented at the ADA 80th Annual Virtual Scientific Sessions.

ADA 2020. Dapagliflozin reduced new onset type 2 diabetes in patients with heart failure with reduced ejection fraction, according to a study released today at the ADA 80th Virtual Scientific Sessions.

ADA2020: Empagliflozin significantly, durably delays need for insulin and for large dose increases, in patients with type 2 diabetes and cardiovascular disease, finds study presented at ADA 80th Scientific Sessions.

ADA 2020: A new automatic insulin delivery system improves glycemic control in young people with type 1 diabetes, according to research presented at the American Diabetes Association Virtual Scientific Sessions.

The American Diabetes Association kicks off its Virtual 80th Scientific Sessions on Friday, June 12, 2020. Here is our guide to top sessions.

Get a snapshot of the diabetes data most important to primary care from the National Diabetes Statistics Report, 2020.

THEMIS trial results showed a statistically significant reduction in risk of MACE with ticagrelor plus aspirin vs aspirin alone in patients with CAD at high risk of first heart attack or stroke.

Diabetes patients are at risk for severe SARS-CoV2 infection. Here, find new evidence-based guidance from an international panel, on how to manage these patients.

FDA has asked 5 US companies to voluntarily recall lots of metformin extended release after detection of NDMA contamination.

Poorly controlled blood glucose in patients with diabetes hospitalized for COVID-19 significantly reduces odds of survival.

The SGLT-2 inhibitor is the first in its class to be approved for the treatment of adults with NYHA class II, III, or IV heart failure with reduced (≤40%) ejection fraction.

For your diabetes patients at home or soon to be at home, use these tips from the ADA and AACE on creating an emergency plan.

These 3 case studies illustrate the challenges of intensifying treatment in complex T2D patients--and also the options available to individualize that next step.

Global leaders in obesity research plus hundreds of medical, scientific, & academic associations and institutions have taken this pledge to end the stigma.

Obesity stigma is pervasive & resilient. A landmark statement demands we eliminate the gap between the social narrative and scientific evidence.

More than 50% of patients with obesity say weight loss is a priority for them. What percentage of their physicians feel the same? #ObesityCareWeek

Irregular sleep patterns in women may impact quality of diet and calories consumed, increasing risk for cardiometabolic disease, concludes a new study.

Liraglutide added to intensive behavior therapy in primary care practice significantly improved weight loss vs behavior therapy alone, a new study found.

Based on results from REWIND, dulaglutide is the first GLP-1 receptor agonist to be approved for both primary and secondary CV prevention in type 2 diabetes.

Weight Watchers (WW), Jenny Craig, and the Nutrarian Diet top the list of 10 best brand-name diet plans. Get highlights here, then find out what your patients are reading.

Which 5 diets are best for your diabetes patients out of the 35 ranked most popular by US News & World Report health experts?

Over 70% of US adults with diabetes have hypertension, 15.6% of these patients have an A1c value >9%, and more fast facts on diabetes risk factors and patient characteristics.

The new 3-in-1 oral therapy may help reduce treatment burden for T2D patients who most often require multiple agents.